Header Logo

Connection

SARA SEXSON TEJTEL to Infliximab

Back to Details
This is a "connection" page, showing publications SARA SEXSON TEJTEL has written about Infliximab.
SARA SEXSON TEJTEL
Connection Strength
0.351
Infliximab
  1. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021 12; 5(12):852-861.
    View in: PubMed
    Score: 0.191
  2. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease. Contemp Clin Trials. 2019 04; 79:98-103.
    View in: PubMed
    Score: 0.159
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.